BASi (Bioanalytical Systems, Inc.) (NASDAQ:BASI) today announced the
launch of Culex® NxT, the latest generation of the Company’s
proprietary in vivo automated sampling system. The Company is now taking
orders for Culex NxT and expects to begin shipping in January.
Developed by BASi to collect pharmacokinetic and pharmacodynamic data,
the Culex system can automatically collect blood, bile, metabolites,
dialysates and more from awake and freely moving animals as small as
mice and as large as swine. The system is used by nine of the world’s
top ten pharmaceutical companies, universities, and contract research
organizations.
"Scientists choose Culex over manual sampling because it delivers better
data, which leads to better decision-making," said Candace
Rohde-Johnson, director of BASi's Instruments Division. "Incorporating
innovative hardware and software improvements, the new Culex NxT has the
same small footprint, robust design and ease of use of the original,
providing its users peace of mind when away from the lab. Culex’s
ability to run experiments around the clock versus just during business
hours significantly increases our clients' efficiency and productivity
in the early stages of drug discovery, including safety pharmacology."
Rohde-Johnson continued, "Culex NxT incorporates what we have learned
from Culex enthusiasts in industry and academia who share best
practices, attend annual user meetings and provide their insights
online. The improved tubing sets, optics, wireless notifications,
quieter operation and in-line glucose monitoring are just some of the
improvements built on this foundation, solidifying Culex as the
preferred instrumentation for automated sampling. We've also made it
easy for current owners to seamlessly and cost-effectively upgrade their
existing systems."
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract research
services and monitoring instruments to the world's leading drug
development companies and medical research organizations. The company
focuses on developing innovative services and products that increase
efficiency and reduce the cost of taking a new drug to market. Visit www.BASinc.com
for more about BASi.
This release contains forward-looking statements that are subject to
risks and uncertainties including, but not limited to, risks and
uncertainties related to changes in the market and demand for our
products and services, the development, marketing and sales of products
and services, changes in technology, industry standards and regulatory
standards, and various market and operating risks detailed in the
company's filings with the Securities and Exchange Commission.
